New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?

Scott, David L

New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice? [electronic resource] - Annals of the rheumatic diseases Jun 2009 - 767-9 p. digital

Publication Type: Editorial; Comment

1468-2060

10.1136/ard.2008.105940 doi


Anti-Inflammatory Agents--economics
Antibodies, Monoclonal--economics
Antibodies, Monoclonal, Humanized
Arthritis, Rheumatoid--drug therapy
Certolizumab Pegol
Cost-Benefit Analysis
Humans
Immunoglobulin Fab Fragments--economics
Patient Selection
Polyethylene Glycols--economics
Randomized Controlled Trials as Topic
Treatment Outcome
Tumor Necrosis Factor-alpha--antagonists & inhibitors